Eric Aguiar, M.D. has been a member of our board of directors since September 2010. He has been a partner at the life
science investment firm Aisling Capital since January, 2016. Prior to joining that firm, he was a partner in the venture capital firm
Thomas, McNerney & Partners since 2007. Dr. Aguiar was a Managing Director of HealthCare Ventures, a healthcare focused venture
capital firm, from 2001 to 2007. He was Chief Executive Officer and a director of Genovo, Inc., a biopharmaceuticals company focused
on gene delivery and gene regulation, from 1998 to 2000. Dr. Aguiar previously served as a director of Amarin Pharmaceuticals, a
publicly-held biopharmaceutical company, as well as on the boards of numerous private companies including companies in the life
sciences industry. He is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on
Foreign Relations. He received an M.D. with honors from Harvard Medical School and a B.A. in Arts and Sciences from Cornell University.
Dr. Aguiar was also a Luce Fellow and is a Chartered Financial Analyst. We believe that Dr. Aguiar is qualified to serve on our board
of directors due to his extensive experience with in the life science field, his experience on various boards, and his management and
financial experience with life sciences companies.
Geoffrey S. Crouse has served on our board of directors since March 2012. Mr. Crouse served as
Chief Executive Officer of Cord Blood Registry (CBR) from September 2012 to August 2015 when the Company was sold to
AMAG Pharmaceuticals. He served as Executive Vice President at AMAG until December 2015. CBR stores stem cells from umbilical
cord blood and tissue. He previously served as Chief Operating Officer at Immucor, Inc., a publicly traded in vitro diagnostics company,
from August 2009 to April 2011. From April 2011 through September 2012, Mr. Crouse was a consultant. Prior to Immucor,
he served as Vice President of the life sciences business at Millipore Corporation, a publicly traded provider of technologies,
tools and services for the life science industry, from 2006 to 2009. Prior to joining Millipore, he worked at Roche, a pharmaceuticals
and diagnostics company, where he held various roles from 2003 to 2006. Mr. Crouse holds a B.A. in English and Japanese from Boston
College and an M.B.A. and Masters of Public Health from the University of California Berkeley. We believe that Mr. Crouse is qualified
to serve on our board of directors due to his extensive experience in the life sciences industry and his management and financial
experience with life sciences companies.
Christine Gorjanc has been on our board of directors and the chair of the Audit Committee since November 2015.
Ms. Gorjanc has served as the Chief Financial Officer of NETGEAR, Inc., a provider of networking products and services, since
January 2008, where she previously served as Chief Accounting Officer from December 2006 to January 2008 and Vice President,
Finance from November 2005 to December 2006. Prior to joining NETGEAR, Inc., Ms. Gorjanc served as Vice President, Controller,
Treasurer and Assistant Secretary for Aspect Communications Corporation, a provider of workforce and customer management solutions,
from September 1996 through November 2005. Ms. Gorjanc served as the Manager of Tax for Tandem Computers, Inc., a provider of
fault-tolerant computer systems, from October 1988 through September 1996. Prior to that, Ms. Gorjanc served in management positions
at Xidex Corporation, a manufacturer of storage devices, and spent eight years in public accounting with a number of accounting firms.
Ms. Gorjanc holds a B.A. in Accounting (with honors) from the University of Texas at El Paso and a M.S. in Taxation from
Golden Gate University. Ms. Gorjanc's experience as an executive and financial expert with a rapidly growing international technology
company operating in highly competitive markets make her well qualified to lead our Audit Committee.